According to the report titled ‘United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025’, available with MarketStudyReport, the United States pneumococcal & meningococcal vaccines market is anticipated to surpass USD 7.5 million by the year 2025.
 

Rising research & development activities by prominent players for vaccine development, soaring cases of meningococcal as well as pneumococcal infections, and government initiatives to raise awareness about these infections and vaccines are driving the growth of United States pneumococcal & meningococcal vaccines market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2090735/

 

However, massive capital expenditures for vaccine development, rigorous regulatory norms, and long production duration are impeding market expansion.

 

Apart from enlisting the drivers and restraints, the research includes a thorough analysis of current industry conditions, opportunities, and size & share predictions through 2025. Also, it presents a comprehensive picture of the market for pneumococcal and meningococcal vaccinations in the United States, both now and in the future.

 

The study includes a detailed analysis of the top six vaccines in the United States from 2015 to 2018, as well as provide estimates through 2025. As per report findings, Trumenba, Menactra, Bexsero, Pneumovax 23, Menveo, and Prevnar/Prevnar 13 are among the promising vaccines that are in clinical testing.
 

Furthermore, it includes the most recent pricing trends and analysis for pneumococcal and meningococcal vaccines. It also looks at the reimbursements patterns and provides a complete overview of the regulatory structure.
 

The competitive landscape of the United States pneumococcal & meningococcal vaccines market includes top companies such as GlaxoSmithKline plc, Pfizer Inc., Merck & Co. Inc., and Sanofi S.A. among others.

 

The aforementioned companies are undertaking various strategies like mergers & acquisitions, partnerships, and alliances in order to strengthen their position in the market. Moreover, an in-depth evaluation of prospective vaccines in clinical development is done, taking into consideration the distribution, license agreements, and exclusivity.